Suvorexant for the treatment of insomnia in patients with psychiatric disorders

Suvorexant for the treatment of insomnia in patients with psychiatric disorders - Suvorexant for insomnia in patients with psychiatric disorders

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024941

Enrollment

Registered

2016-11-22

Start date

2016-09-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psychiatric disorders

Interventions

All the subjects received a fixed dose of suvorexant (20 mg if ages 18-64 or 15 mg if age more than 64 years) for seven consecutive nights.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients meet the following inclusion criteria (4days > or = one week): sleep latency > or = 30 minutes, total sleep time < 6 hours, wake after sleep onset > 1.

Exclusion criteria

Exclusion criteria: Patients meet contraindication of suvorexant Patients with substance abuse or dependence (excluding nicotine and caffeine) meeting DSM-IV-TR criteria Patients having severe physical disease Patients who are pregnant or may become pregnant Patients who had made suicide attempt within the past year

Design outcomes

Primary

Measure	Time frame
sleep latency, total sleep time, wake After Sleep Onset	—

Secondary

Measure	Time frame
individual adverse events	—

Countries

Japan

Contacts

Public ContactTaro Kishi

Fujita Health University School of Medicine Department of Psychiatry

tarok@fujita-hu.ac.jp0562-93-9250

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026